Your browser is no longer supported. Please, upgrade your browser.
RNLX [NASD]
Renalytix Plc
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand36.02M Perf Week-4.04%
Market Cap688.94M Forward P/E950.00 EPS next Y0.02 Insider Trans- Shs Float5.91M Perf Month-19.15%
Income- PEG- EPS next Q-0.12 Inst Own16.70% Short Float5.72% Perf Quarter-39.08%
Sales1.02M P/S676.09 EPS this Y72.30% Inst Trans1.25% Short Ratio3.37 Perf Half Y-29.84%
Book/sh2.41 P/B7.88 EPS next Y5.70% ROA- Target Price- Perf Year65.22%
Cash/sh2.05 P/C9.25 EPS next 5Y- ROE- 52W Range9.91 - 35.71 Perf YTD18.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.79% Beta-
Dividend %- Quick Ratio21.20 Sales past 5Y- Gross Margin- 52W Low91.79% ATR1.99
Employees17 Current Ratio21.20 Sales Q/Q- Oper. Margin- RSI (14)35.84 Volatility6.73% 8.96%
OptionableYes Debt/Eq0.01 EPS Q/Q-305.60% Profit Margin- Rel Volume1.18 Prev Close19.22
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume100.30K Price19.00
Recom2.50 SMA20-16.31% SMA50-26.83% SMA200-26.82% Volume118,429 Change-1.14%
Jul-02-21Initiated Berenberg Buy $38
Aug-11-20Initiated Stifel Buy
Sep-14-21 07:00AM  
Sep-09-21 06:03AM  
Sep-03-21 07:00AM  
Aug-30-21 07:00AM  
06:36AM  
Aug-26-21 07:00AM  
Aug-03-21 06:16AM  
Jul-28-21 07:00AM  
Jul-26-21 07:00AM  
Jul-22-21 07:00AM  
Jul-16-21 06:19AM  
Jul-11-21 08:43AM  
Jun-28-21 07:00AM  
Jun-15-21 07:00AM  
Jun-10-21 08:00AM  
Jun-07-21 07:00AM  
Jun-03-21 07:00AM  
Jun-02-21 11:34AM  
11:34AM  
May-19-21 07:00AM  
May-04-21 02:20PM  
Apr-22-21 07:00AM  
Apr-20-21 07:21AM  
07:00AM  
Apr-14-21 07:00AM  
Apr-08-21 07:00AM  
Apr-05-21 07:00AM  
Mar-15-21 07:00AM  
Mar-10-21 10:31AM  
Mar-04-21 01:00PM  
Mar-02-21 07:00AM  
06:30AM  
Feb-24-21 08:00AM  
Feb-23-21 02:00AM  
Feb-10-21 11:31AM  
Feb-08-21 07:30AM  
Feb-04-21 07:00AM  
Jan-13-21 02:00AM  
Jan-06-21 08:54AM  
07:30AM  
Jan-05-21 06:00AM  
Jan-04-21 08:05AM  
Nov-29-20 11:42AM  
Nov-25-20 07:30AM  
07:00AM  
Nov-13-20 02:00AM  
Nov-06-20 07:00AM  
Nov-02-20 10:30AM  
Oct-28-20 07:30AM  
Oct-27-20 03:00AM  
Oct-26-20 07:30AM  
Sep-22-20 07:00AM  
Sep-18-20 07:00AM  
Aug-26-20 07:00AM  
Aug-21-20 03:00AM  
Aug-03-20 08:00AM  
Jul-27-20 08:00AM  
Jul-21-20 03:57PM  
Jul-16-20 11:38PM  
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. Renalytix AI plc was founded in 2018 and is based in Cardiff, the United Kingdom.